We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The risk predictive values of UK- PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
- Authors
Yang, F.; Yang, Y.; Wang, Q.; Wang, Z.; Miao, Q.; Xiao, X.; Wei, Y.; Bian, Z.; Sheng, L.; Chen, X.; Qiu, D.; Fang, J.; Tang, R.; Gershwin, M. E.; Ma, X.
- Abstract
Background Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis ( PBC). The UK- PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. Aim To validate the UK- PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti-gp210 as a biomarker, and to investigate whether anti-gp210 could affect the prognostic values of UK- PBC and GLOBE scoring systems. Methods We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti-gp210+ and 143 anti-gp210− patients. Results The 5-year adverse outcome-free survivals of anti-gp210+ vs. anti-gp210− patients were 70% and 85%, respectively ( P = 0.005). Cirrhosis ( P = 0.001), albumin level ≤40 g/L ( P = 0.011) and platelet count ≤153 × 109 ( P < 0.001) had a superimposition effect on anti-gp210 antibody as a risk factor. Furthermore, long-term prognoses were evaluated using the UK- PBC and GLOBE scores. For UK- PBC scoring system, the area under receiver operating characteristic curve ( AUROC) was 0.924 for all patients with PBC ( n = 223), 0.940 for anti-gp210+ patients ( n = 110) and 0.888 for anti-gp210− patients ( n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC ( n = 223), 0.924 for anti-gp210+ patients ( n = 110) and 0.848 for anti-gp210− patients ( n = 113). UK- PBC score >0.0578 ( P < 0.001, HR: 32.736, 95% CI: 11.368-94.267) and GLOBE score <0.850 ( P < 0.001, HR: 18.763, 95% CI: 7.968-44.180) were associated with poorer outcomes in the whole cohort. Conclusions The UK- PBC and GLOBE scoring systems were good 5-year prognostic predictors in Chinese patients with PBC, especially in anti-gp210+ patients. As a biomarker, anti-gp210 antibody was associated with a more severe cholestatic manifestation and a worse long-term prognosis. The anti-gp210 antibody could be added to further optimise the UK- PBC and GLOBE scoring systems.
- Subjects
HEALTH of Chinese people; BILE duct diseases; CHOLANGITIS; GLYCOPROTEINS; PATIENTS; THERAPEUTICS
- Publication
Alimentary Pharmacology & Therapeutics, 2017, Vol 45, Issue 5, p733
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/apt.13927